Print section
Print Rubric:
A young biotech firm focused on cancer promises both risk and reward
Print Headline:
The trials of Juno
Print Fly Title:
Biotechnology
UK Only Article:
standard article
Issue:
The threat from Russia
Fly Title:
Biotechnology
Main image:
20161022_wbp501_hr.jpg
IN THE pharma business, Juno Therapeutics, a small firm based in Seattle, is just a stripling. It is three years old, has not a single drug approval to its name but is nonetheless valued at $2.8 billion. That value is derived from the fact that it is on the forefront of the most promising area of cancer treatments in decades: immuno-oncology.
Juno’s edge comes from its attempts to master one of the most important parts of the immune system: the T-cell. It is developing a so-called CAR-T therapy, in which its scientists extract T-cells from a cancer patient, modify them with …Original Article
